EMERYVILLE, Calif.,
April 15, 2014 /PRNewswire/
-- Adamas Pharmaceuticals, Inc. (Adamas) (Nasdaq:ADMS), a
specialty pharmaceutical company, today announced the closing of
its initial public offering of 3,000,000 shares of its common stock
at a public offering price of $16.00 per share. The
shares began trading on The NASDAQ Global Market under the ticker
symbol "ADMS" on April 10, 2014. Adamas estimates net proceeds
from the offering to be approximately $41.5 million after
deducting underwriting discounts and commissions and estimated
offering expenses.
Credit Suisse and Piper Jaffray
acted as joint book-running managers for the proposed
offering. William Blair and
Needham & Company acted as co-managers.
A registration statement relating to these securities was
declared effective by the U.S. Securities and Exchange
Commission on April 9, 2014.
The offering was made only by means of a written prospectus
forming part of the effective registration statement. A copy
of the final prospectus relating to these securities may be
obtained from Credit Suisse Securities (USA) LLC, by mail at Attention: Prospectus
Department, One Madison Avenue, New York,
NY 10010, or by telephone at +1 (800) 221-1037, or by e-mail
at newyork.prospectus@credit-suisse.com, or Piper Jaffray & Co., by mail at 800 Nicollet
Mall, Suite 1000, Minneapolis, MN
55402, or by telephone at +1 (800) 747-3924, or by e-mail at
prospectus@pjc.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical
company driven to improve the lives of those affected by chronic
disorders of the central nervous system. Adamas achieves this by
enhancing the pharmacokinetic profiles of approved drugs to create
novel therapeutics for use alone and in fixed-dose combination
products. Adamas is currently developing its lead wholly owned
product candidate, ADS-5102, for a complication of Parkinson's
disease known as levodopa induced dyskinesia and as a treatment for
chronic behavioral symptoms associated with traumatic brain
injury.
SOURCE Adamas Pharmaceuticals, Inc.